文献速递前列腺癌

Revo-i机器人系统行保留Retzius间隙前列腺癌根治术:首例人体试验

Retzius-sparing robot-assisted radical prostatectomy using the Revo-i robotic surgical system: surgical technique and results of the first human trial.
PubMed 文献 · BJU Int · 2018-05-27

前瞻性研究纳入17例临床局限性前列腺癌患者,2016年8月至2017年2月使用Revo-i机器人平台完成保留Retzius间隙机器人辅助根治性前列腺切除术(RS-RARP)。主要目的是描述手术技术并评估30天内安全性,同时评估早期肿瘤学与控尿结局。所有手术均成功完成,无中转开放或腹腔镜,围术期、早期肿瘤学及控尿结果令人鼓舞。

要点

  • Revo-i机器人系统可安全完成RS-RARP,无中转开放或腹腔镜。
  • 中位 docking 时间8分钟、控制台时间92分钟、吻合时间26分钟、出血200 mL。
  • 3个月时4例切缘阳性、1例生化复发、15例控尿。

核心结论

  • Revo-i机器人系统治疗局限性前列腺癌的首个人体研究成功完成,围术期、早期肿瘤学与控尿结果令人鼓舞。

研究设计与样本

  • 前瞻性研究,纳入2016年8月17日至2017年2月23日在本院泌尿外科接受Revo-i治疗的17例临床局限性前列腺癌患者,均行RS-RARP。

主要发现

  • 所有手术均成功完成,无中转开放或腹腔镜。
  • 中位患者年龄72岁,中位对接时间8分钟、控制台时间92分钟、尿道膀胱吻合时间26分钟、估计出血量200 mL。
  • 3个月时4例切缘阳性、1例生化复发、15例控尿(不使用或仅使用1个尿垫)。
  • 大多数外科医生对Revo-i性能满意(Likert量表评估)。

临床怎么用

  • Revo-i机器人平台可用于临床局限性前列腺癌的RS-RARP,需关注围术期输血风险并评估早期切缘、生化复发与控尿。

局限性

  • 需进一步前瞻性研究支持初步结果。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To evaluate the safety and proficiency of the Revo-i® robotic platform (Meere Company Inc.) in the treatment of prostate cancer (PCa). PATIENTS AND METHODS: A prospective study was carried out on 17 patients with clinically localized PCa treated between 17 August 2016 and 23 February 2017 at our urology department using the Revo-i. Patients underwent Retzius-sparing robot-assisted radical prostatectomy (RS-RARP). The primary objective was to describe the RS-RARP step-by-step surgical technique using the Revo-i. In addition, the safety of the Revo-i was assessed according to intra-operative and the postoperative complications within 30 days of surgery. Early oncological outcomes were also assessed according to surgical margin status and biochemical recurrence (BCR). Continence was defined as use of no or only one pad. Surgeons' satisfaction with the Revo-i was assessed using the Likert scale. RESULTS: All surgeries were completed successfully, with no conversion to open or laparoscopic surgery. The median patient age was 72 years. The median docking time, console time, urethrovesical anastomosis time and estimated blood loss were 8 min, 92 min, 26 min and 200 mL, respectively. One patient was transfused intra-operatively as a result of blood loss of 1 500 mL. Postoperatively, two patients received blood transfusion, and there were no other serious/major complications. The median hospital stay was 4 days. At 3 months, four patients had positive surgical margins, one patient had BCR, and 15 patients were continent. Most of surgeons were satisfied with the Revo-i performance. CONCLUSIONS: The first human study for the treatment of patients with localized PCa using the Revo-i robotic surgical system was carried out successfully. The peri-operative, early oncological and continence outcomes are encouraging. Further prospective studies are warranted to support our preliminary results.

来源:BJU Int,查看原文。版权归原作者所有。

引用

  1. Chang KD, Abdel Raheem A, Choi YD, et al. Retzius-sparing robot-assisted radical prostatectomy using the Revo-i robotic surgical system: surgical technique and results of the first human trial. BJU Int. 2018. PMID: 29645348. doi:10.1111/bju.14245

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。